I agree that this site is using cookies. You can find further informations here.
X
Bergua Burgues, Juan
142  results:
Search for persons X
?
1

A phase 3 trial of azacitidine versus a semi‐intensive flud..:

Vives, Susana ; Martínez‐Cuadrón, David ; Bergua Burgues, Juan...
Cancer.  127 (2021)  12 - p. 2003-2014 , 2021
Link: https://doi.org/10.1002/..
 
?
2

Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecifi..:

Martin-Sanchez, Esperanza ; Blanco Fernández, Laura ; Kim, Peter S....
Blood Advances.  , 2024
Link: https://doi.org/10.1182/..
 
?
3

Clinical outcomes after CPX‐351 in patients with high‐risk ..:

Bernal, Teresa ; Moreno, Ainhoa Fernández ; de LaIglesia, Almudena...
Cancer Medicine.  12 (2023)  14 - p. 14892-14901 , 2023
Link: https://doi.org/10.1002/..
 
?
4

S130: PRELIMINARY RESULTS OF QUIWI: A DOUBLE BLINDED, RANDO..:

Montesinos, Pau ; Rodríguez-Veiga, Rebeca ; Bergua Burgues, Juan Miguel...
HemaSphere.  7 (2023)  S3 - p. e734771d , 2023
Link: https://doi.org/10.1097/..
 
?
5

Extranodal natural killer/T‐cell lymphoma nasal type in a w..:

Gonzalez Barca, Eva ; Tomás‐Roca, Laura ; Esteve, Anna...
American Journal of Hematology.  98 (2023)  6 - p. , 2023
Link: https://doi.org/10.1002/..
 
?
6

Integrated flow cytometry and sequencing to reconstruct evo..:

Simoes, Catia ; Chillon, Maria-Carmen ; Martínez-Cuadrón, David...
Blood Advances.  7 (2023)  1 - p. 167-173 , 2023
Link: https://doi.org/10.1182/..
 
?
7

Safety and efficacy of tafasitamab with or without lenalido..:

Belada, David ; Kopeckova, Katerina ; Bergua Burgues, Juan Miguel...
Blood.  142 (2023)  16 - p. 1348-1358 , 2023
Link: https://doi.org/10.1182/..
 
?
8

A prospective biomarker analysis of alvocidib followed by c..:

Zeidner, Joshua F. ; Lin, Tara L. ; Vigil, Carlos E....
Blood Cancer Journal.  11 (2021)  10 - p. , 2021
Link: https://doi.org/10.1038/..
 
?
9

S132: UPDATED RESULTS OF VEN-A-QUI STUDY: A PHASE 1-2 TRIAL..:

Miguel Bergua Burgues, Juan ; Rodríguez-Veiga, Rebeca ; Cano Ferri, Isabel...
HemaSphere.  7 (2023)  S3 - p. e8385270 , 2023
Link: https://doi.org/10.1097/..
 
?
10

P498: INCIDENCE, RISK FACTORS AND OUTCOMES OF SECOND NEOPLA..:

Sobas, Marta ; Knopinska-Posluszny, Wanda ; Piątkowska-Jakubas, Beata...
HemaSphere.  7 (2023)  S3 - p. e835897e , 2023
Link: https://doi.org/10.1097/..
 
?
11

P531: MIDOSTAURIN PLUS 7 + 3 OR QUIZARTINIB PLUS 7 + 3 IN F..:

Tormo, Mar ; Diaz-Beya, Marina ; Beneit, Paola...
HemaSphere.  7 (2023)  S3 - p. e4025574 , 2023
Link: https://doi.org/10.1097/..
 
?
12

P-213 COVALENT-101: phase I study of BMF-219, a covalent me..:

Rosenberg, Aaron ; Baljevic, Muhamed ; Amor, Adrian Alegre...
Clinical Lymphoma Myeloma and Leukemia.  23 (2023)  - p. S152-S153 , 2023
Link: https://doi.org/10.1016/..
 
?
13

P492: SAFETY AND EFFICACY OF LP-108 AS MONOTHERAPY AND COMB..:

Koenig, Kristin ; Miguel Bergua Burgues, Juan ; Montesinos, Pau...
HemaSphere.  7 (2023)  S3 - p. e2546261 , 2023
Link: https://doi.org/10.1097/..
 
?
14

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphami..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S358-S359 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclop..:

Flowers, Christopher ; Tilly, Hervé ; Morschhauser, Franck...
Clinical Lymphoma Myeloma and Leukemia.  22 (2022)  - p. S163 , 2022
Link: https://doi.org/10.1016/..
 
1-15